After characterizing the natural history of erosive activity, we next assessed the differential capacity for specific bones to recover with anti-TNF therapy towards defining biomarkers to evaluate pharmaceutical treatments efficiently and accurately in the TNF-Tg preclinical model of arthritis. This evidence concerns the gene TNF and Arthritis.